Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis sees gene,...

    Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-05T09:15:35+05:30  |  Updated On 16 Aug 2021 4:52 PM IST

    ZURICH: Novartis sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss newspaper reported on Wednesday, after the Swiss drugmaker held an event with German-language media on research and development.


    Steven Moran, Novartis's global head of strategy, said expectations regarding cell and gene therapies should "not get carried away", the Neue Zuercher Zeitung reported.


    Novartis confirmed Moran's comment and said company representatives have indicated previously they project revenue from cell and gene therapies, as well as so-called radioligand therapy for diseases like cancer, making up 15-20% of revenue that last year totaled around $45 billion.


    Novartis has made big investments in the $475,000-per-patient blood cancer therapy Kymriah, $850,000 in its blindness treatment Luxturna, and $2.1 million one-time gene therapy Zolgensma, which it bought with the $8.7 billion Avexis takeover in 2018.


    Revenue from cell and gene therapies now represents a fraction of Novartis's annual sales. Kymriah's sales in 2018 were $76 million and $58 million in the second quarter. The Basel-based company has said it would release Zolgensma sales details after the third quarter.


    Read Also: Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals


    Zolgensma won U.S. approval this year but is now the subject of a Food and Drug Administration investigation over alleged data manipulation. The U.S. Senate has also demanded information, while Novartis Chief Executive Vas Narasimhan has said his company has "exited" some Avexis scientists following an internal probe.


    Read Also: Delhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug Ceritinib

    blood cancer therapycancergene therapyKymriahNovartispharmapharma companypharma newsSteven MoranSwiss drugmakerSwiss newspaper
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok